Table 4.
Parameters | Univariate Logistic Regression | Multivariate Logistic Regression | ||||||
---|---|---|---|---|---|---|---|---|
p Value | OR | 95% CI | p Value | OR | 95% CI | |||
Lower | Higher | Lower | Higher | |||||
Age ≥65 years | 0.094 | 0.607 | 0.339 | 1.088 | 0.221 | 0.643 | 0.316 | 1.305 |
Male | 0.506 | 1.244 | 0.654 | 2.367 | – | – | – | – |
History of HB | 0.002 | 2.759 | 1.448 | 5.256 | 0.148 | 2.004 | 0.781 | 5.144 |
History of HC | 0.995 | 1.007 | 0.111 | 9.146 | – | – | – | – |
History of drink | 0.496 | 1.196 | 0.714 | 2.005 | – | – | – | – |
History of cirrhosis | 0.795 | 1.070 | 0.641 | 1.787 | – | – | – | – |
Primary HCC | 0.015 | 2.437 | 1.193 | 4.977 | 0.325 | 1.958 | 0.513 | 7.465 |
Primary ICC | 0.071 | 0.328 | 0.098 | 1.099 | – | – | – | – |
Secondary liver cancer | 0.154 | 0.544 | 0.235 | 1.257 | – | – | – | – |
Multifocal disease | 0.009 | 0.498 | 0.295 | 0.840 | 0.151 | 0.595 | 0.293 | 1.208 |
Tumor location: left liver | 0.163 | 1.596 | 0.828 | 3.077 | – | – | – | – |
Tumor location: right liver | 0.230 | 1.371 | 0.819 | 2.297 | – | – | – | – |
Tumor location: bilobar | 0.022 | 0.500 | 0.277 | 0.904 | 0.316 | 0.686 | 0.328 | 1.434 |
Largest nodule size ≥5 cm | 0.003 | 0.442 | 0.259 | 0.755 | 0.111 | 0.574 | 0.291 | 1.135 |
Portal vein invasion | 0.001 | 0.258 | 0.119 | 0.559 | 0.010 | 0.253 | 0.088 | 0.722 |
Hepatic vein invasion | 0.086 | 0.429 | 0.164 | 1.126 | 0.934 | 0.948 | 0.271 | 3.315 |
Higher ECOG performance status | 0.010 | 0.581 | 0.385 | 0.877 | 0.489 | 0.836 | 0.503 | 1.390 |
Higher Child–Pugh Stage | 0.244 | 0.637 | 0.298 | 1.360 | – | – | – | – |
Higher BCLC Stage | 0.008 | 0.625 | 0.441 | 0.885 | 0.774 | 1.068 | 0.683 | 1.668 |
Two or more cycles of DEB-TACE treatment | 0.908 | 0.960 | 0.482 | 1.913 | – | – | – | – |
Previous cTACE treatment | 0.491 | 1.202 | 0.712 | 2.027 | – | – | – | – |
Previous surgery | 0.845 | 0.945 | 0.537 | 1.663 | – | – | – | – |
Previous systematic chemotherapy | 0.398 | 0.693 | 0.297 | 1.621 | – | – | – | – |
Previous radiofrequency ablation | 0.098 | 0.471 | 0.193 | 1.148 | 0.121 | 0.462 | 0.174 | 1.227 |
Previous targeted therapy | 0.776 | 0.800 | 0.171 | 3.733 | – | – | – | – |
Higher DEBs size | 0.286 | 0.326 | 0.042 | 2.551 | – | – | – | – |
Higher drug dosage | 0.424 | 1.488 | 0.555 | 3.988 | – | – | – | – |
Combination of ordinary embolization agent | 0.253 | 0.715 | 0.401 | 1.272 | – | – | – | – |
WBC abnormal | 0.965 | 0.987 | 0.550 | 1.770 | – | – | – | – |
RBC abnormal | 0.332 | 0.765 | 0.445 | 1.315 | – | – | – | – |
ANC abnormal | 0.072 | 0.559 | 0.296 | 1.054 | 0.379 | 0.722 | 0.349 | 1.492 |
Hb abnormal | 0.187 | 0.699 | 0.411 | 1.190 | – | – | – | – |
PLT abnormal | 0.593 | 1.152 | 0.685 | 1.939 | – | – | – | – |
ALB abnormal | 0.024 | 0.522 | 0.297 | 0.917 | 0.466 | 0.773 | 0.387 | 1.545 |
TP abnormal | 0.331 | 1.324 | 0.752 | 2.333 | – | – | – | – |
TBIL abnormal | 0.339 | 1.318 | 0.748 | 2.322 | – | – | – | – |
TBA abnormal | 0.753 | 1.091 | 0.635 | 1.874 | – | – | – | – |
ALT abnormal | 0.762 | 0.907 | 0.483 | 1.705 | – | – | – | – |
AST abnormal | 0.031 | 0.541 | 0.310 | 0.944 | 0.725 | 0.884 | 0.445 | 1.755 |
ALP abnormal | 0.142 | 0.660 | 0.380 | 1.148 | – | – | – | – |
BCr abnormal | 0.951 | 0.976 | 0.449 | 2.121 | – | – | – | – |
BUN abnormal | 0.146 | 0.545 | 0.241 | 1.234 | – | – | – | – |
AFP abnormal | 0.267 | 0.746 | 0.445 | 1.252 | – | – | – | – |
CEA abnormal | 0.178 | 0.643 | 0.338 | 1.223 | – | – | – | – |
CA199 abnormal | 0.558 | 0.841 | 0.471 | 1.501 | – | – | – | – |
Data are presented as p value, OR (odds ratio), and 95% CI (confidence interval). Factors affecting CR achievement were determined by univariate logistic regression analysis, while all factors with p value no more than 0.1 were further detected by multivariate logistic regression analysis. A value of p < 0.05 was considered significant (bold). Child–Pugh stage was scored as 0—A, 1—B, 2—C; BCLC stage was scored as 0—stage 0, 1—stage A, 2—stage B, 3—stage C, 4—stage D. The logistic analysis was performed based on these definitions.